PHARMACEUTICAL COMPOUNDS AND METHODS OF USE.

Abstract

The present invention relates to topical pharmaceutical compositions comprising a corticosteroid and an insecticide selected from pyrethrin or a synthetic pyrethroid insecticide. Methods for their use in the treatment of allergic dermatitis, particularly hypersensitivity to insect bites, in animals using the compositions of the invention are also described.

Description

PHARMACEUTICAL COMPOUNDS AND METHODS OF USE This application claims priority over Australian Provisional Application No. 2019903522 entitled Pharmaceutical Compositions and Methods of Use, filed on September 23, 2019, the contents of which are incorporated herein by reference in their entirety. FIELD OF INVENTION The present invention relates to topical pharmaceutical compositions comprising a corticosteroid and an insecticide selected from pyrethrin or a synthetic pyrethroid insecticide. Methods for their use in the treatment of lesions and pruritus associated with allergic dermatitis, particularly hypersensitivity to insect bites, in animals are also described. BACKGROUND OF THE INVENTION Allergic dermatitis due to insect bites is a common condition in animals. It occurs worldwide wherever the animal and the respective parasite coexist and is particularly prevalent in warmer climates. Allergic dermatitis from insect bites can affect domestic animals such as sheep, cattle, pigs, horses, and dogs. It is particularly common in horses and dogs and is by far the most common cause of skin disease in these domestic animals. An allergy is a hypersensitivity or altered state of the immune system that causes it to damage itself. Within animal groups, only a few are affected. There are four different types of immune reactions to an allergen. The most common type, and the one predominantly involved in clinical syndromes of hypersensitivity to insect stings, is an IgE-mediated immune reaction, although cell-mediated reactions involving IgE III and IV antibodies can also occur. In type I immunopathology, allergen-specific IgE binds to an antigen on a mast cell, activating degranulation and the subsequent release of histamine, serotonin, eotaxin, and other cytokines. This leads to inflammation and the attraction of other inflammatory cells. In the case of insect bite hypersensitivity, the allergens are primarily salivary antigens, specifically 11 proteins from the salivary glands of Culicoides spp. (mosquito) identified as insect bite hypersensitivity (IBH) allergens in horses (Schaffartzik et al., Veterinary Immunology and Immunopathology 147 (2012) 113-126) and numerous Ctenocephalides felis (cat flea) saliva proteins identified as allergens in dogs (Lee et al., Veterinary Immunology and Immunopathology 69 (1999) 229-237). The degree of stimulation of IgE responses depends on the characteristics of the antigen and the genetic factors of the affected individual. The insect model demonstrates both the protective and potentially destructive nature of immune system responses. The irritation from an insect bite can cause the host to react by expelling or killing the insect, and under normal circumstances, the immune response can change, leading to an allergy, that is, a decrease in reactivity. On the other hand, if the individual has a genetic predisposition, hypersensitivity develops, resulting in persistent inflammation, which is intensified and prolonged by self-trauma from rubbing, biting, and scratching.Furthermore, the release of histamine and other inflammatory factors, such as eicosanoids, causes increased blood flow and vascular permeability at the site of the reaction, leading to an itching response and further skin damage through self-trauma. This cycle of itching, scratching, skin damage, and more itching causes continuous tissue damage and suffering in the animals. This abnormal and long-lasting hypersensitivity is believed to have a genetic basis in horses. For example, a study of Warmblood horses in the Czech Republic showed that the rate of the condition in the offspring of certain stallions varied significantly, ranging from 10% to 75% (Raskova et al., J. Equine Vet. Sci. 2013; 33(6):427-432), which supports the genetic predilection model. Conversely, no hereditary relationship was established, and no breed predilection was identified (Miller et al., Muller & Kirk's Small Animal Dermatology, 7th ed. St. Louis, MO: Elsevier / Mosby, 2013; 4072013). Horses are commonly affected by IBH caused by Culicoides spp. (biting midges). The disease is colloquially known as Queensland itch in Australia and sweet itch in the Northern Hemisphere. While Culicoides spp. is the most commonly implicated parasite, Tabanus and Chrysops spp. (horse flies), Stomoxys spp. (stable flies), Simulium spp. (black flies), and Musca spp. (houseflies), as well as bees and wasps, can all cause lesions and hypersensitivity reactions on the horse's skin. In dogs, the most common form of insect-induced allergic dermatitis is flea allergy dermatitis (FAD). Ctenocephalides felis (the cat flea) is the primary parasite involved, although C. canis may also be present. The term summer itch or summer eczema / dermatitis is also used colloquially for the condition in both horses and dogs, as both are seasonal during the summer months. Clinical signs differ among animal species; however, there are similarities in their dorsal distribution and intense itching. In horses, Culicoides spp. feeds on the dorsal surface, predominantly along the mane and tail area and around the face and ears. Even in animals without hypersensitivity, the bite of the Culicoides midgeon can be particularly painful due to its mouthparts. ML / t / zuzz / u^u^oy MA / t / masticator. In dogs, clinical signs associated with FAD include pruritic papular dermatitis on the rump, dorsal thorax, flanks, trunk, and perineal area. In severe cases, a generalized distribution may occur. Some dogs may develop severe acute lesions, such as acral lick granuloma or pyotraumatic dermatitis on the rump or one side of the face. A horse or dog whose irritation progresses to a state of hypersensitivity will exhibit signs ranging from thinning of the hair or coat and papules and wheals to alopecia, crusting, excoriations, hypopigmentation, and lichenification. When the skin becomes secondarily infected, the pruritus often worsens. Staphylococci are commonly involved in these secondary infections. Both IBH and FAD are known to cause significant suffering and distress to affected animals worldwide. Many treatments have been developed for the disease, with varying degrees of success and, in some cases, harmful results. In theory, eradicating all biting insects (i.e., environmental control) to which the animal is allergic will resolve the dermatitis, but in most circumstances, this may be difficult or impossible to achieve. Therefore, treatment must involve both minimizing insect bites and managing the pruritus resulting from the allergic reaction. To date, there is no single treatment that addresses both of these requirements, nor a formulation with a practical and reasonable dosing interval. There are several drawbacks to current management and treatment approaches. Environmental control of Culicoides species is difficult. Their life cycle is poorly understood, which hinders environmental control. During the summer, development from egg to adult takes a couple of weeks. Like fleas, some larvae and pupae overwinter in protected breeding sites and continue their development in warmer climates. Mosquitoes breed in humid conditions in various habitats, particularly in damp, muddy areas and in fecal and plant matter. Adult mosquitoes typically live for about 20 days, and depending on environmental conditions, they can live for more than 90 days. Adults fly and mate in swarms. Like fleas, female mosquitoes need to feed on blood for their eggs to mature. They typically lay between 100 and 200 eggs in areas with specific humidity levels and abundant organic matter.The development from egg to adult usually takes about 15 days, but can last up to seven months during the hibernation period. Modifying these areas by removing organic matter and draining muddy areas is an important part of the strategy for controlling Culicoides reproduction; however, achieving complete control is still difficult. Environmental flea control is easier, since all stages of reproduction occur indoors and in the yard. Flea extermination and vacuuming of indoor areas, as well as treating all pets, can yield good results. Preventing exposure to biting insects is the cornerstone of current treatment protocols. For example, stabling horses at dawn and dusk and using fans at those times will reduce the number of Culicoides midges that access the animal. If fans cannot be used, then it may be helpful to place screens over windows and around doors in enclosed areas of the stables. In the summer months, stabling is typically required between 4 pm and 8 am. In warmer climates, such as subtropical to tropical Australia, close stabling is not as readily available as in more temperate climates like Europe, where horses can be stabled for much of the time. Many Australian horses are routinely kept on pasture year-round, with only shade trees and other open structures providing shelter.To avoid exposure to mosquitoes, carpeting is often used; however, this is not suitable in hot summer conditions. Furthermore, damage to carpets caused by horses rubbing against fences and trees requires frequent and costly repairs and replacements. It is often impractical or impossible to completely eliminate insects from the environment or to provide physical protection against fleas or mosquitoes. Chemical repellents can be used to try to prevent insect bites. Insect repellents based on natural pyrethrin are extracted from the flowers of certain chrysanthemum species, particularly Chrysanthemum cinerariifolium. Insect control products based on synthetic pyrethroids are commonly used for their insect-repellent activity on both dogs and horses. These synthetic pyrethroids are more potent, have less odor, last longer, and can be used at lower concentrations than natural pyrethrins (see, for example, the ChemicalWATCH fact sheet: https: / / www.beyondpesticides.org / assets / media / documents / mosquito / documents / SyntheticPyr ethroids.pdf). Type I pyrethroids include allethrin, bifenthrin, permethrin, phenothrin, resmethrin, tefluthrin, and teramethrin. Type II pyrethroids include cyfluthrin, cyhalothrin, cypermethrin, deltamethrin, fenvalerate, fenpropathrin, flucythrinate, flumethrin, fluvalinate, and tralometrine. One disadvantage of synthetic pyrethroids is that chemical modifications to the structure of natural pyrethrin to increase stability and insect-repellent efficacy often result in an increased irritant potential of the product. Those that have a Cyano group compounds tend to be more irritating. This is particularly noticeable in second-generation pyrethroids, such as permethrin. To avoid irritation, the concentration of permethrin can be decreased; however, this has a negative effect on efficacy. As a result of the need to reduce or avoid irritation, insect control products often do not contain a high enough concentration of permethrin to be effective as insect repellents. Instead, a product containing pyrethrin, a first-generation compound, is used. Pyrethrin is about four times less effective than permethrin and less stable. Commonly available insecticide treatments for horses include daily application of 40 g / L of 2% diluted permethrin as a spray or rinse, or 87 g / L of permethrin for weekly pour application. Piperonyl butoxide in combination with permethrin can be applied to horses or dogs as a spray or rinse twice daily or twice weekly. These treatments have drawbacks such as frequent application and / or skin irritation. Weekly pour application of 200 g / L of fenvalerate to horses causes irritation. Twice-daily application of 89 g / L of citronella oil and 51 g / L of N,N-diethyl-M-toluamide to dogs or horses has poor efficacy against fleas and midges and a short duration of effect. Applying the permethrin / citronella combination every other day by spraying or rinsing to dogs or horses has a very short duration of activity.Twice-daily application by spraying or rinsing of a benzoyl benzoate / bronopol formulation is used to treat secondary skin infections in dogs or horses. It has little efficacy against fleas and midges; furthermore, bronopol is a known cause of allergic dermatitis. Several products are available for treating dogs, but not horses, that can be used to ensure that if a flea infests the animal, it dies quickly. This reduces feeding time and therefore prevents or reduces exposure to the allergen in the saliva. These products include topical treatments containing permethrin, fipronil, or indoxacarb. Typically, these can be applied to the back of the animal's neck and subsequently spread through the epidermal lipids. These products, often referred to as spot treatments, require frequent application and avoid bathing for several days before and after application. In some cases, these products may become less effective as fleas develop resistance. Systemic flea treatments for dogs are also commercially available. These are usually in the form of monthly or quarterly chewable tablets containing active ingredients such as spinosad, afoxolaner, or fluralaner. Like spot-on topical treatments, they do not act as a repellent and require the flea to feed on the dog to ingest the active ingredient and die. However, mortality times are relatively rapid. These products have the disadvantage of being relatively expensive (Pucheu-Haston et al., Practica! Parasitology: The Flea Infested Pet: Overview of Current Products. Today's Vet. Pract. 7: 90-95). Topical and systemic glucocorticoids are used to treat the allergic component of the disease in dogs. Topical polypharmacy creams are commonly used. These typically include a corticosteroid, a local anesthetic, and an antibiotic. These polypharmacy compositions have the disadvantage of containing an antibiotic component, which may not be necessary and can lead to potentially inappropriate administration, potentially exacerbating the development of resistance. Corticosteroid sprays are also available, containing, for example, hydrocortisone aceponate in an alcohol base. After application, the vehicle evaporates, leaving the active ingredient on the skin. This can cause a burning sensation on damaged skin and should be used carefully to avoid further distressing the animal. Oral prednisolone is commonly used in dogs while flea control is taking effect. Normal doses are approximately 1 mg / kg / day and are then gradually reduced. Common side effects of oral prednisolone can include panting, lethargy, increased thirst and urination, and increased appetite, all of which can be concerning for both the animal and the owner. Prolonged use of oral prednisolone can lead to symptoms of hypercortisolism, such as abnormal fat metabolism, hair loss, and thinning of the skin. Systemic corticosteroids used in horses to treat the allergic component of the disease include short courses (1–2 weeks) of oral prednisolone at a dose of 1 mg / kg per day. Alternatively, a convenient but potentially dangerous long-acting injectable corticosteroid may be administered in combination with other treatment methods until pruritus is relieved or reduced. These long-acting injectable corticosteroids, such as triamcinolone acetonide, dexamethasone, and methylprednisolone acetate, typically induce an increase in the adverse side effects of steroids and continued suppression of the hypothalamic-pituitary-adrenal axis.In addition, all systemic corticosteroids are contraindicated in pregnant mares, horses with a history of laminitis, those with equine Cushing's syndrome or equine metabolic disease, and those with any other internal organ complications. Hi antihistamines can be used to relieve the symptoms of allergic insect bite dermatitis; however, they do not provide a real advantage over [other antihistamines]. Glucocorticoids are not recommended, as they have limited efficacy in reducing pruritus. Furthermore, antihistamines can also induce mild sedation and behavioral or personality changes in the animal. Alternative forms of treatment were attempted, such as desensitization using immunotherapy; however, this appears to induce little response in both horses and dogs (Ginel, et al., Vet. Dermatol. 2014; 25:29-e 10). Recent criteria using blocking analogues or monoclonal antibodies that inactivate inflammatory cytokines are promising for horses and have demonstrated efficacy in dogs for flea allergy (Michaels, et al., Vet. Dermatol. 2016; 27:478-e 129). Their true value in insect bite allergy remains to be evaluated. However, given the required research contribution, this criterion is expected to be expensive in horses, as is the case with cytokine blockers currently marketed for dogs. Furthermore, the long-term effects of blocking this immune pathway are unknown. Popular and relatively accessible remedies, such as washing animals with oatmeal shampoo, were used to provide some relief, and the application of other natural or readily available remedies, such as calamine lotion, was suggested, although neither is effective as a standalone treatment and their benefit is minimal. The use of dietary supplements containing, for example, essential fatty acids, has increased in recent years, but limited data are available to support their effectiveness. Similarly, traditional or natural remedies, such as garlic supplementation, were suggested for both flea control and inflammation management, but there is insufficient data to support any real benefit. It is clear that the complexity of insect bite allergy dermatitis, the prevalence of the parasites worldwide, and the resulting suffering and reduced quality of life of affected animals, along with the concern and cost to owners, justify the development of a more effective treatment that addresses one or more of the drawbacks of currently available treatments. In particular, there is a need for treatments that are more effective, easy to use, have convenient application intervals, are readily available, or are cost-effective. BRIEF DESCRIPTION OF THE INVENTION Advantageously, the inventor discovered that topical compositions comprising a corticosteroid in combination with a pyrethrin or pyrethroid insecticide are useful in the treatment of allergic insect bite dermatitis, or insect bite hypersensitivity, in mammals. In preferred embodiments, the compositions further comprise one or more silicone excipients. Topical formulations eliminate the need for systemic corticosteroids. Therefore Therefore, the compositions are considered safe for use as they have minimal systemic toxicity or side effects. The formulations are convenient and easy to use. In addition, the formulations are fast-acting and provide rapid relief to animals suffering from allergic reactions. Accordingly, in a first aspect, a pharmaceutical composition for topical application is provided comprising, consisting of, or essentially consisting of a corticosteroid; an insecticide selected from pyrethrin insecticides and pyrethroid insecticides; and a pharmaceutically acceptable vehicle. Preferably, the composition is for application to the skin and / or fur of an animal. In preferred embodiments, the compositions also comprise one or more silicones. In another aspect, a method is provided for treating allergic insect bite dermatitis in a mammal, comprising the topical administration of an effective amount of a composition comprising, consisting of, or essentially consisting of a corticosteroid and an insecticide selected from pyrethrin insecticides and pyrethroid insecticides to a mammal in need. In another aspect, a topical composition is provided comprising, consisting of, or essentially consisting of a corticosteroid and an insecticide selected from pyrethrin insecticides and pyrethroid insecticides for use in the treatment of allergic insect bite dermatitis. In another aspect, the use of a topical composition comprising, consisting of, or essentially consisting of a corticosteroid and an insecticide selected from pyrethrin insecticides and pyrethroid insecticides is provided in the manufacture of a medicament for the treatment of allergic insect bite dermatitis. In some forms, the corticosteroid is budesonide. In some forms, the insecticide is permethrin. In some formulations, the composition comprises budesonide in an amount of approximately 0.2 g / L to approximately 1 g / L, for example, about 0.25 g / L; and permethrin in an amount of approximately 20 g / L to approximately 80 g / L, for example, about 40 g / L. The composition is preferably formulated in a base comprising one or more conditioning excipients, for example, one or more silicones. In some forms, the composition comprises one or more silicones with a total of approximately 25 g / L to approximately 150 g / L of the composition, for example, approximately 75 g / L of the composition. In some forms, the pharmaceutical composition is a conditioner, a leave-in conditioner, a lotion, a spray, a cream, an ointment ML / t / ZUZZ / U4U40U or a pouring formulation. In some formulations, the pharmaceutical formulation is adapted for application, preferably to the animal's skin, coat, or fur, by pouring or spraying. In other formulations, the composition is designed to be smoothed onto the animal's coat. In some forms, the mammal is an equine or a canine. In another aspect, a pharmaceutical composition formulated for topical administration is provided, comprising, consisting of, or essentially consisting of: a corticosteroid in an amount of approximately 0.025 g / L to approximately 1 g / L, or 0.15 g / L to approximately 1 g / L; a pyrethrin insecticide or a pyrethroid insecticide in an amount of approximately 0.5 g / L to approximately 50 g / L; one or more silicones in an amount of approximately 25 g / L to approximately 150 g / L; at least one pharmaceutically acceptable excipient; and a pharmaceutically acceptable aqueous vehicle. In another aspect, a pharmaceutical composition formulated as a leave-in (or rinse-out) conditioner for topical administration is provided, comprising, consisting of, or essentially consisting of: budesonide in an amount of approximately 0.25 g / L; permethrin in an amount of approximately 40 g / L; one or more silicones in a combined amount of approximately 75 g / L; thickening agents in an amount of approximately 30 g / L; one or more pharmaceutically acceptable excipients selected from solubilizing agents, chelating agents, antioxidants and pH adjusters; and a pharmaceutically acceptable aqueous vehicle, preferably purified water. Preferably, the composition was formulated for or adapted for application to the skin, coat or fur of an animal. A method is also provided for treating insect bite allergic dermatitis in a mammal by topical application, preferably to the skin, fur or hair of the mammal, of a pharmaceutical composition as described herein, to a mammal in need. BRIEF DESCRIPTION OF THE FIGURES Figure 1 is a graphical representation showing the comparative mean lesion scores and standard deviations for each of the treatment groups in a randomized controlled clinical trial of a permethrin and budesonide formulation for the topical treatment of horses suffering from Culicoides allergy. The scores of the ML / t / zuzz / u^u^oy lesions in all treatment groups are shown on days 0, 21 and 42. Figure 2 is a graphical representation showing the itch score for each of the treatment groups in the clinical study of a permethrin and budesonide formulation for the topical treatment of horses suffering from Culicoides allergy. The itch score was measured daily for 42 days using the visual analog scale for pruritus. Figure 3 is a graphical representation summarizing the overall treatment response in each of the treatment groups in the clinical study. A 4-level scale from 1 (poor) to 4 (excellent) was used as a measure of overall improvement and was assessed by a veterinarian on days 21 and 42. DETAILED DESCRIPTION OF THE INVENTION Definitions Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by persons with basic expertise in the field to which the invention pertains. Although any method and material similar or equivalent to those described herein may be used in the practice or testing of the present invention, preferred methods and materials are described. For the purposes of the present invention, the following terms are defined below. The articles "un" and "una" are used here to refer to one or more than one (i.e., at least one) of the grammatical object of the article. For example, "un elemento" means one element or more than one element. Approximately means a quantity, level, value, number, frequency, percentage, dimension, size, amount, weight, or length that varies as much as 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1% from a reference quantity, level, value, number, frequency, percentage, dimension, size, amount, weight, or length. The term around is interpreted similarly. When the terms % w / w, % w / v, and % v / v are used here, they mean weight / weight, weight / volume, and volume / volume percentages, respectively. Amounts stated as “g / L” mean grams of component per liter of composition. As used herein, the term and / or refers to and encompasses all, any and all possible combinations of one or more of the associated listed elements, as well as the lack of combinations when interpreted in the alternative (or). Throughout this specification and the claims that follow, unless the context requires otherwise, the word "comply" and variations such as "comprises" and "that comprises" shall be understood to imply the inclusion of a stated integer or step or group of integers or steps, but not the exclusion of any other integer or step or group of integers or steps. Therefore, the use of the term "that comprises" and The phrase "similar" indicates that the listed whole numbers are necessary or mandatory, but that other whole numbers are optional and may or may not be present. "Consisting of" is understood to include and be limited to everything following the phrase "consisting of." Therefore, the phrase "consisting of" indicates that the listed items are necessary or mandatory, and that no other items can be present. "Consisting essentially of" is understood to include any items listed after the phrase and is limited to other items that do not interfere with or contribute to the activity or action specified in the disclosure of the listed items. Therefore, the phrase "consisting essentially of" indicates that the listed items are required or mandatory, but that other items are optional and may or may not be present depending on whether or not they affect the activity or action of the listed items. When used herein, the term "topical," when used in terms such as topical application, topical administration, topical medicament, topical formulation, and the like, refers to the application of a composition or formulation to the animal's body surfaces, such as the skin, hair, fur, or mucous membranes. In some preferred modalities, the body surface is the animal's skin, hair, or fur. When used herein, the term corticosteroid refers to steroidal anti-inflammatory pharmaceutical agents. Appropriately, the corticosteroid is adapted for topical application. Preferably, the corticosteroid is a glucocorticoid. Conveniently, the glucocorticoid is an approved or registered pharmaceutical product suitable for animal use selected from, but not limited to, alclomethasone; amcinonide; betamethasone; budesonide; clobetasol; clobetasone; desonide; desoximethasone; diflucortolone; diflorasone; fluocinolone; fluocinonide; flurandrenolide; fluticasone; halcinonide; halobetasol; halomethasone; hydrocortisone; mometasone; methylprednisolone; triamcinolone; and / or a salt, solvate, and / or derivative of any of the same. In some formulations, the glucocorticoid is either hydrocortisone or budesonide. In one form, the glucocorticoid is alclometasone dipropionate; amcinonide; betamethasone dipropionate; betamethasone valerate; budesonide; clobetasol propionate; clobetasone butyrate; desonide; desoximetasone; diflucortolone valerate; diflorasone diacetate; fluocinolone acetonide; fluocinonide; flurandrenolide; fluticasone propionate; halcinonide; halobetasol propionate; halometasone; hydrocortisone; hydrocortisone aceponate; hydrocortisone butyrate; hydrocortisone 17-butyrate; hydrocortisone valerate; mometasone furoate; methylprednisolone acetonide; or triamcinolone acetonide. In some forms, the glucocorticoid is budesonide. When used here, the term pyrethrin or pyrethrin insecticide refers to a naturally occurring pyrethrin compound extracted from the flowers of certain chrysanthemum species, particularly Chrysanthemum cinerariifolium. The potent insecticidal activity of pyrethrins is achieved through their effect on the nervous system of insects. However, those skilled in the field will appreciate that the effectiveness of a pyrethrin insecticide can be due to its insecticidal and / or insect-repellent properties. The insecticidal and repellent effects of pyrethrins are covered here. Examples of naturally occurring pyrethrins include pyrethrin I, pyrethrin II, cinerin I, cinerin II, jasmolin I, and jasmolin II. Natural pyrethrins can be used individually or in combination with two or more of these compounds. When used here, the term pyrethroid or pyrethroid insecticide refers to a synthetic pyrethroid compound. Pyrethroids are synthetic versions of the naturally occurring pyrethrin structure and undergo chemical modifications to increase their stability and insect-repellent and / or insecticidal efficacy. Pyrethroid compounds include, but are not limited to, allethrin I, allethrin II, bioallethrin, bifenthrin, permethrin, phenothrin, resmethrin, tefluthrin, cyfluthrin, tetramethrin, cyhalothrin, cypermethrin, deltamethrin, fenvalerate, fenpropathrin, flucythrinate, flumethrin, fluvalinate, and tralomethrin. In some formulations, permethrin is a pyrethroid insecticide. When the term silicone excipient or silicone is used herein, it means a siloxane and includes siloxanes such as cyclosiloxanes and polysiloxanes. Silicones are well known in the field and are readily available from commercial sources such as The Dow Chemical Co. Silicones are widely used in the formulation of pharmaceutical compositions, cosmetics, and personal care products. Examples of silicones include, but are not limited to, at least one cyclosiloxane selected from cyclopentasiloxane and cyclotetrasiloxane or a mixture thereof and polydimethylsiloxane with a terminal hydroxyl group. In some embodiments, combinations of two or more silicones may be incorporated into a composition according to the invention to impart desired physical properties to the composition.For example, polydimethylsiloxane with a terminal hydroxyl group (dimethiconol, poly[oxy(dimethylsilylene)], α-hydro-ω-hydroxy-) is a highly viscous siloxane that has emollient properties and can provide a soft, silky feel and condition the animal's coat, fur, or skin. Cyclosiloxanes, such as mixtures of cyclopentasiloxane and cyclotetrasiloxane, provide lubricating and dispersing properties. When used in the compositions described here, silicone mixtures can provide a conditioning effect on the animal's skin, coat, or fur. The term insect bite allergy dermatitis encompasses hypersensitivity skin reactions in animals to insect bites due to specific protein allergens in the insect's saliva. Insect bite allergy dermatitis may also be called insect bite hypersensitivity (IBH). The condition is commonly found in warm regions and can affect many species of insects. MA / t / zuzz / u+u^ou mammals, such as domestic mammals, including dogs and horses. Typically, the biting insect may be a mosquito or a flea, although it should be understood that the type of insect is not so limited. Common biting insects include, for example, Culicoides spp. and Ctenocephalides spp., such as C. felis or C. canis. Other examples of biting insects include Forcipomyia spp., for example, Forcipomyia taiwana. It should be appreciated that the species of biting insect will vary according to factors such as the specific geographic region or climate. Allergic insect bite dermatitis in horses is usually caused by Culicoides spp. and is commonly known as Culicoides hypersensitivity allergic reaction. It is also known as seasonal recurrent dermatitis, Queensland itch, or sweet itch. Allergic reactions typically occur on the animal's skin in areas where the insects feed, such as the mane, tail, and dorsal midline. Ventral symptoms may also be present. Skin lesions around the ears, face, and head are also commonly found. In dogs, typical symptoms of insect bite allergy dermatitis include pruritic papular dermatitis on the rump, back, flanks, trunk, or perineal area. Severe lesions include acral lick granuloma or pyotraumatic dermatitis. Symptoms of allergic dermatitis from insect bites may include, but are not limited to, one or more of the following: dry, cracked, or scaly skin; rash; redness; itching, including severe itching; swelling; burning; fragility; tenderness; lesions; papules or wheals, which may be accompanied by oozing or crusting; hair loss; excoriations; hypopigmentation; and lichenification. A particularly distressing symptom for the affected animal is the skin lesions accompanied by intense itching. This causes the animal to rub, often roughly, resulting in considerable self-trauma. This can lead to coat damage, bald patches, and broken, bleeding skin. Secondary infections, such as bacterial or fungal infections, especially skin infections, may also occur. Common secondary bacterial infections include staphylococcal infections. When used here, the term derivative includes chemical modifications introduced into the structure of a corticosteroid molecule. Common corticosteroid derivatives include derivatives of steroid hydroxyl substituents, for example, esters, ethers, and ketals, such as cyclic ketals like acetonides. For example, hydrocortisone can be derivatized to form an ester such as hydrocortisone aceponate, hydrocortisone butyrate, hydrocortisone 17-butyrate, or hydrocortisone valerate. A corticosteroid molecule can be derivatized at one or more sites. MA / IZ / ¿U¿¿ / U4U40» Ester derivatives of corticosteroids are well known in this field. Common ester derivatives of steroid hydroxyl groups, particularly the 17- or 21-hydroxyl groups, include acetate, propionate, butyrate, valerate, pivalate, succinate, benzoate, salicylate, and 2-furoate. When a corticosteroid has two ester derivatives, examples include diacetate, dipropionate, divalerate, valeroacetate, acetate / propionate (aceponate), and butyrate / propionate (butiprate). Cyclic ketal derivatives, such as acetonides, can be formed through two adjacent hydroxyl groups in the steroid structure, for example, 16- and 17-hydroxyl substituents. As used herein, the terms salts and solvates include any pharmaceutically acceptable salt or solvate of an active pharmaceutical ingredient. Pharmaceutically acceptable salts are well known in the field. Corticosteroid salts include sodium salts, including sodium salts of derivatives, for example, sodium succinates. Pharmaceutically acceptable solvates are well known in this field and include hydrates and alcoholates. Specifically, pharmaceutically acceptable solvates include hydrates, such as monohydrates, dihydrates, and trihydrates. The preparation of salts, derivatives, and solvates can be carried out using methods well known in the field. The chemical structures of the corticosteroids or insecticides used according to the invention may include asymmetric centers, such as asymmetric carbon atoms. It will be appreciated that the isomers arising from such asymmetry (e.g., all enantiomers, stereoisomers, diastereomers, rotamers, or racemates) are included within the scope of this invention. Where stereochemistry is not specified, it will be understood that the structure is intended to encompass any stereoisomer and all mixtures thereof. For example, the corticosteroid budesonide [1ip,21-dihydroxy-16a,17a-(butyldenobis(oxy))pregna-1,4-diene-3,20-dione, alternatively ip,21-dihydroxy-16a,17a-[butane-1,1-diylbis(oxy)]pregna-1,4-diene-3,20-dione] can have a (22R) or (22S) configuration. The chemical structures of the corticosteroids or insecticides used according to the invention may include geometric isomers due to the presence of, for example, a carbon-carbon double bond. It will be appreciated that, unless otherwise stated, all geometric isomers, such as cis / trans geometric isomers, are included within the scope of this invention. Where stereochemistry is not specified, it will be understood that the structure is intended to encompass any geometric isomer and all mixtures thereof. Permethrin may exist as a cis or trans isomer or a mixture thereof; for example, permethrin may be a 25:75 cis:trans mixture. ML / t / zuzz / u^u^ou MA / The term subject, individual, mammal, or animal, as used herein, refers to a mammalian subject for whom therapy or prophylaxis is desired. In particular modalities, the subject is a domestic mammal, for example, an equid, including but not limited to horses, ponies, donkeys, mules; a camelid, including but not limited to camels, llamas, and alpacas; dogs; sheep; cattle; pigs; and goats. Preferably, the mammal is selected from cattle, pigs, sheep, dogs, or horses. In some modalities, the mammal is selected from cattle, pigs, sheep, goats, dogs, or horses. In some modalities, the mammal is a dog. In some modalities, the mammal is an equine, for example, a horse or pony. In some modalities, the mammal is a goat. The terms relieve, treat, treated, inhibit, or treatment as used herein cover the treatment of insect bite allergic dermatitis and / or a symptom of insect bite allergic dermatitis and include: inhibiting the condition, i.e., stopping its development; relieving the condition, i.e., causing the condition to regress; or relieving the resulting symptoms of the condition without addressing the underlying disease or condition. Each modality described herein shall be applied mutatis mutandis to each and every modality unless specifically stated otherwise. Compositions of the invention The compositions of the invention find use in the treatment or inhibition of insect bite allergic dermatitis or the symptoms associated with insect bite allergic dermatitis. The present invention is based on the surprising discovery that a pharmaceutical composition formulated for topical application comprising a corticosteroid; an insecticide selected from a pyrethrin or a pyrethroid and a pharmaceutically acceptable vehicle provides access to an effective and convenient treatment for allergic insect bite dermatitis. The pharmaceutical compositions described here comprise a combination of an insecticidal or insect repellent agent with a corticosteroid anti-inflammatory agent. The components are readily available and provide a cost-effective treatment for allergic insect bite dermatitis. In preferred formulations, the compositions include a topical corticosteroid, such as hydrocortisone or budesonide. These topical corticosteroids are largely metabolized in the skin, with only 0.4 to 0.7% reaching systemic levels, thus minimizing the possibility of systemic side effects such as those typically associated with systemic corticosteroids. In some formulations, the topical spheroid is a soft or dissociative spheroid.These spheroids are androstene-derived spheroids that exhibit anti-inflammatory effects similar to those of conventional corticosteroids, but without the potentially serious systemic side effects associated with some conventional steroids. In preferred formulations, the corticosteroid is a glucocorticoid suitable for topical application. In some formulations, the glucocorticoid is selected from glucocorticoids that, when applied to the skin of a mammal, are not substantially absorbed systemically. Preferred glucocorticoids are those that are substantially metabolized in the skin, thereby reducing or minimizing any undesirable systemic effects. Examples of suitable glucocorticoids are well known in the field. In some formulations, the glucocorticoid is selected from alclomethasone; amcinonide; betamethasone; budesonide; clobetasol; clobetasone; desonide; desoximethasone; diflucortolone; diflorasone; fluocinolone; fluocinonide; flurandrenolide; fluticaseone; halcinonide; halobetasol; halomethasone; hydrocortisone; mometasone; methylprednisolone; triamcinolone; and / or a salt, solvate and / or derivative thereof.In some formulations, the corticosteroid is hydrocortisone or a salt and / or solvate, for example, hydrocortisone aceponate. In certain specific formulations, the corticosteroid is budesonide or a salt and / or solvate and / or derivatives thereof. In some formulations, the insecticide is a natural pyrethrin insecticide such as pyrethrin I, pyrethrin II, cinerin I, cinerin II, jasmolin I, or jasmolin II, or a mixture of two or more of these. Pyrethrins are extracted from the dried flowers of certain chrysanthemum species, particularly Chrysanthemum cineranifolium, which is commercially cultivated, for example, in Kenya. Isolated pyrethrins are readily available from commercial sources. In some embodiments, the insecticide is a synthetic pyrethroid insecticide. Synthetic pyrethroid insecticides are well known in the field and are commercially available. It will be appreciated that the pyrethroid compound is suitable for application to an animal's skin. Pyrethroid insecticides include, but are not limited to, allethrin I, allethrin II, bioallethrin, bifenthrin, permethrin, phenothrin, resmethrin, tefluthrin, cyfluthrin, tetramethrin, cyhalothrin, cypermethrin, deltamethrin, fenvalerate, fenpropathrin, flucythrinate, flumethrin, fluvalinate, and tralomethrin. In some embodiments, the pyrethroid insecticide is permethrin. Permethrin exists as cis and trans geometric isomers. In the compositions described herein, the permethrin may comprise a single geometric isomer or may comprise both isomers as a mixture. In some forms, permethrin is a mixture of cis and trans isomers in a ratio of approximately 25:75. The amount of corticosteroid present in the composition will depend on the type of formulation and how it will be applied. For example, a typical formulation in ointment, cream, lotion, conditioner, leave-in conditioner, pour-on, or spray form may contain a corticosteroid in an amount of approximately 0.025 g / L to approximately 0.5 g / L or from approximately 0.025 g / L to approximately 1 g / L. ML / t / zuzz / u^u^oy g / L; from approximately 0.05 g / L to approximately 0.5 g / L or from approximately 0.05 g / L to approximately 1 g / L; or from approximately 0.1 g / L to approximately 0.5 g / L or from approximately 0.05 g / L to approximately 1 g / L; for example from approximately 0.05 g / L to approximately 0.6 or 0.8 g / L, or from approximately 0.1 g / L to approximately 0.5 g / L; from approximately 0.15 g / L to approximately 0.5 g / L; from approximately 0.1 g / L or 0.15 g / L to approximately 0.4 g / L; from approximately 0.2 g / L to approximately 0.4 g / L; from approximately 0.1 g / L to approximately 0.3 g / L; from approximately 0.15 g / L to approximately 0.5 g / L; from approximately 0.2 g / L to approximately 0.5 g / L; from approximately 0.15 g / L to approximately 0.35 g / L; from approximately 0.15 g / L to approximately 0.45 g / L; from approximately 0.2 g / L to approximately 0.4 g / L; from approximately 0.25 g / L to approximately 0.5 g / L; from approximately 0.25 g / L to approximately 0.4 g / L; from approximately 0.2 g / L to approximately 0.3 g / L; and especially approximately 0.25 g / L. It will be appreciated that, if the application of the composition involves rinsing, such as a shampoo or washing formulation, this may require a higher concentration of corticosteroids. The amount of insecticide present in the composition will depend on the type of formulation and the application method. Typically, the formulation may comprise a pyrethrin or pyrethroid insecticide in an amount of approximately 0.5 g / L to approximately 60 g / L, approximately 0.5 g / L to approximately 50 g / L, or approximately 1 g / L to approximately 50 g / L; for example, approximately 5 g / L to approximately 50 g / L, approximately 10 g / L to approximately 45 g / L, approximately 20 g / L to approximately 40 g / L, approximately 30 g / L to approximately 45 g / L, or approximately 35 g / L to approximately 45 g / L, and especially approximately 40 g / L. In some embodiments, the composition comprises a pyrethrin or pyrethroid insecticide in an amount of up to 10, 15, 20, 25, 30, 35, 40 or 45 g / L. In some embodiments, the composition comprises a pyrethrin or pyrethroid insecticide in an amount of at least 5, 10, 15, 20, 25, 30, or 35 g / L.It will be noted that if the application of the composition involves rinsing, such as a shampoo or wash formulation, this may require a higher concentration of corticosteroids. In some embodiments, the corticosteroid is present in a composition of the invention in an amount of approximately 0.0025% w / w to approximately 0.1% w / w. In some embodiments, the corticosteroid is present in an amount of approximately 0.005% w / w to approximately 0.1% w / w; approximately 0.0075% w / w to approximately 0.1% w / w; approximately 0.01% w / w to approximately 0.075% w / w; approximately 0.01% w / w to approximately 0.05% w / w; approximately 0.02% w / w to approximately 0.04% w / w; approximately 0.02% w / w to approximately 0.3% w / w; or approximately MA / 0.025% w / w. In some formulations, the corticosteroid is present in an amount of approximately 0.015% w / w; approximately 0.1% w / w; approximately 0.015% w / w; approximately 0.1% w / w; approximately 0.01% w / w; approximately 0.04% w / w; approximately 0.01% w / w; approximately 0.05% w / w; approximately 0.02% w / w; approximately 0.04% w / w; approximately 0.02% w / w; or approximately 0.025% w / w. In some embodiments, the insecticide is present in a composition of the invention in an amount of approximately 0.05% w / w to approximately 5.0% w / w. In some embodiments, the corticosteroid is present in an amount of approximately 0.1% w / w; approximately 0.15% w / w; approximately 0.1% w / w; approximately 0.01% w / w; approximately 4% w / w; approximately 0.01% w / w; approximately 4.5% w / w; approximately 0.02% w / w; approximately 4% w / w; or approximately 4% w / w. In some formulations, the ratio of corticosteroid to pyrethrin or pyrethroid insecticide is approximately 1:100 to approximately 1:200 by weight, for example, approximately 1:125 to approximately 1:175 by weight, or approximately 1:140 to approximately 1:170 by weight. In some formulations, the ratio of corticosteroid to pyrethrin or pyrethroid insecticide is approximately 1:160 by weight. When a composition of the invention includes one or more silicones, it will be appreciated that the amount of silicone components present will depend on the type of formulation and how it is to be applied. In some compositions such as those described herein, such as leave-in lotions or conditioners, the ratio of API (insecticide and corticosteroid) to the combined amount of silicones is approximately 1:2 to 2:1 or approximately 1:2 to 3:2, for example, approximately 40:70 or 41:75. In its simplest form, the composition of the invention may comprise a corticosteroid; an insecticide selected from pyrethrin and pyrethroid insecticides; and a pharmaceutically acceptable vehicle. Those skilled in the art will appreciate that the composition may also include other pharmaceutically acceptable additives, such as surfactants, emulsifiers, rheology or viscosity modifiers, solvents or solubilizing agents, buffering agents, pH adjusters, diluents, dispersing agents, chelating agents, preservatives, antioxidants, stabilizers, toning agents, humectants, thickeners, and excipients. The compositions preferably comprise one or more silicones as conditioning excipients. The inventor discovered that compositions of the invention comprising one or more silicones are particularly advantageous. Silicones provide properties such as film-forming properties, wash resistance, and spreadability to a composition. Silicones can also provide soothing and emollient properties and, therefore, can provide a calming effect on the skin or conditioning of the animal's skin, coat, or fur. In some embodiments, the presence of one or more silicones in a composition of the invention provides an emollient effect. This emollient effect may be due to the formation of a residual layer or silicone film on the animal's skin, which forms a water-repellent barrier (see, for example, https: / / luisafanzani.com / what-is-dimeticone / ). Accordingly, in another aspect, the present invention advantageously provides a pharmaceutical composition for topical application comprising, consisting of, or essentially consisting of: a corticosteroid; a pyrethrin insecticide or pyrethroid insecticide; one or more silicones; and a pharmaceutically acceptable aqueous vehicle; and, optionally, one or more pharmaceutically acceptable excipients. In some forms, one or more silicones are present in a composition in an amount of approximately 25 g / L to approximately 150 g / L, for example, approximately 50 g / L to approximately 100 g / L, approximately 60 g / L to approximately 90 g / L, approximately 70 g / L to approximately 80 g / L, or approximately 75 g / L. In some preferred embodiments, the silicone-containing composition is formulated as a conditioner, leave-in conditioner, or lotion. Conveniently, the composition is packaged in a pump dispenser adapted to release a predetermined amount of composition per pump. In some embodiments, the composition of the invention is a leave-in conditioner formulation, also called a rinse-out conditioner, for application to the skin, coat, or fur of the animal, comprising one or more silicones. The expert will appreciate that the physical properties of silicones vary according to their chemical structure and will be able to select the appropriate silicones according to the desired final physical properties of the composition. Suitable silicones are well known in the field, and one or more silicones can be selected to impart properties such as increased or reduced viscosity, film-forming properties, wash resistance, spreadability, volatility, or permeability to a composition. The quantity and type of silicone(s) present in a composition of the invention can be adjusted according to the needs of the animal and will depend on the species, for example, dog or horse. ML / t / ZUZZ / U4U40U that factors such as the type of animal, the condition and chronicity of the disease, the length of the coat, oiliness and the general condition of the skin or hair can be taken into account when formulating a composition.In some embodiments, the composition comprises one or more silicones selected from cyclopentasiloxane, cyclotetrasiloxane, and hydroxyl-terminal polydimethylsiloxane. In some embodiments, combinations of two or more silicones can be incorporated into a composition according to the invention to impart the desired physical properties. In some examples, the composition comprises cyclopentasiloxane, cyclotetrasiloxane, and hydroxyl-terminal polydimethylsiloxane. Suitable silicones and silicone blends are readily available from commercial sources. Examples include Xiameter® PMX-0344 or Xiameter® PMX-1401, available from The Dow Chemical Company. Xiameter® PMX-0344 is a cyclosiloxane blend comprising cyclopentasiloxane and cyclotetrasiloxane. This silicone blend can act as a base fluid and has good lubrication and spreadability properties and unique volatility characteristics.Xiameter® PMX-1401 is a 13% solution of a combination of dimethiconol (terminal hydroxyl polydimethylsiloxane) in cyclopentasiloxane and cyclotetrasiloxane. The terminal hydroxyl polydimethylsiloxane can act as an emollient and, therefore, can provide a soft feel to the skin and condition the hair and coat. Dimethiconol is a highly viscous polysiloxane silicone. In some embodiments of the invention, dimethiconol is present in a composition of the invention in an amount of approximately 0.5 g / L to 3 g / L; for example, from approximately 1 g / L to 2.5 g / L; or approximately 2 g / L; or approximately 1.95 g / L. Cyclosiloxanes comprising a mixture of cyclopentasiloxane and cyclotetrasiloxane may be present in a composition in an amount of approximately 25 g / L to approximately 125 g / L; for example, from approximately 50 g / L to approximately 100 g / L; 60 g / L to approximately 80 g / L; or approximately 70 g / L to 75 g / L; for example, approximately 73%. In another aspect, a pharmaceutical composition formulated for topical administration is provided, comprising, consisting of, or essentially consisting of: one or more silicones in an amount of approximately 0.025 g / L to approximately 1 g / L, a pyrethrin insecticide or a pyrethroid insecticide in an amount of approximately 0.5 g / L to approximately 50 g / L; one or more cyclosiloxanes in an amount of approximately 25 g / L to approximately 150 g / L, for example, approximately 50 g / L to approximately 100 g / L; At least one polysiloxane, such as dimethiconol, in an amount of approximately 1 MA / IZ / ¿U¿¿ / U4U40» g / L to approximately 3 g / L, for example, approximately 2 g / L. at least one pharmaceutically acceptable excipient; and a pharmaceutically acceptable aqueous vehicle. Topical administration according to the invention may be by means of any formulation suitable for releasing the active ingredients onto the skin or coat of the animal. Topical formulations are well known in the field and are described, for example, in Ueda et al., Topical and Transdermal Drug Products, Pharmacopeial Forum, Vol. 35 (3), 2009; Buhse et al., Topical Drug Classification, International Journal of Pharmaceutics, 2005, 295, 101-112. Suitable formulations include, but are not limited to, liquids, sprays, creams, ointments, lotions, foams, gels, shampoos, conditioners, and leave-in conditioners. In some embodiments, the pharmaceutically acceptable vehicle is an aqueous vehicle, for example, water, such as purified water. In some formulations, the composition is a liquid, such as an aqueous solution. Liquids can be applied to the animal's coat or skin by any suitable means, for example, by washing, soaking, dipping, spraying, aerosolizing, pouring, or back-line application. The liquid may be a ready-to-use formulation or supplied as a concentrate to be diluted with an aqueous diluent, such as water, before application. The concentration of the composition will depend on the intended method of administration. For example, a composition for spraying, dipping, soaking, washing, or pouring may be a more dilute formulation than a composition for application by pouring or spraying on the back. Back-line application formulations are ready-to-use liquids that can be applied to animals, such as cattle, sheep, pigs, or horses, by pouring along the back from the neck to the tail.In some formulations, the composition can be supplied in a spray bottle for application by spraying, such as that dispensed by a trigger sprayer. Other suitable application methods are known, for example, a moistened gauze pad, swab, cotton ball, foam, sponge, or cloth. In some cases, the composition can be applied manually to the skin or coat. In some embodiments, the composition of the invention is a cream or lotion. Creams are semi-solid, multi-phase compositions containing the active agents, in this case the corticosteroid and the insecticide, each dissolved in a suitable base. Creams include water-in-oil or oil-in-water emulsions, or microcrystalline aqueous dispersions of fatty acids or long-chain alcohols, and generally have a relatively soft, spreadable consistency. In some preferred formulations, the composition is in the form of a lotion. Lotions share many characteristics with creams and are typically an emulsion, solution, or viscous suspension. They usually contain an aqueous vehicle and more than 50% water and volatile compounds. Lotions are easy to apply and, being water-based, easy to remove. They can have an emollient effect and may leave a cooling or soothing sensation on the animal's skin. In some formulations, where the composition is to be applied topically to hairy skin, it may be in the form of a shampoo or conditioner. Conditioners, such as hair conditioners, are well-known in hair care. Such conditioner formulations are particularly useful for application to parts of an animal's body with hair. The inventor discovered that conditioner compositions are useful formulations for the compositions of the invention. The inventor also identified that the compositions of the invention formulated as a leave-in conditioner (also called a no-rinse conditioner) are particularly advantageous. A leave-in conditioner is a conditioning product that can be applied to the hair, skin, or fur of an animal. Leave-in conditioners generally include silicones. Such conditioning formulation bases and excipients are well known and are described, for example, in Barel et al., Handbook of Cosmetic Science and Technology, Third Edition, 2009. ORO Press. Page 687. The presence of silicones in the leave-in conditioners of the present invention provides a conditioning and emollient effect due to the provision of water repellency through the formation of a residual film or barrier on the animal's coat. The leave-in conditioners allow penetration into the coat and coat the hair with a residual film of medication. The leave-in conditioners of the present invention demonstrate several advantages over other forms of topical application. For example, applying a spray formulation can frighten or stress an already anxious animal, especially a horse. Semi-solid dosage forms, such as creams, require massage to penetrate the coat. Animals often resist massage on sensitive skin, and the massaging action can cause the coat to mat, preventing the cream from being spread and applied correctly. Leave-in conditioner formulations are lighter and less viscous than standard conditioners and provide a thin residual layer of the formulation on the animal's coat, hair, or skin. In their simplest form, leave-in conditioners can be used to restore lost moisture to the skin and hair. In the compositions of the invention, in addition to treating the symptoms of IBH, leave-in conditioners provide a conditioning and / or emollient effect due to the residual film, which can provide water repellency. This is advantageous, as exposing skin lesions to water can exacerbate the animal's suffering. The conditioner can be ML / t / zuzz / u^u^oy can be applied to an animal's coat at any time; however, it is preferably applied to the coat of a freshly bathed animal. The coat may be dry, damp, or wet, but preferably the animal's coat is damp. The leave-in conditioner formulations of the present invention are easy and quick to apply and limit the amount of discomfort or stress experienced by the animal. They provide rapid relief. They are cost-effective and long-lasting, so they do not require frequent reapplication. Leave-in lotions and conditioners are dispensed from a pump dispenser, which can be configured to dispense a predetermined dose and quantity of the product. In some examples, a pump is configured to dispense approximately 1.6 mL or 1.5 g of a leave-in lotion or conditioner per pump. The compositions of the invention can be prepared using conventional methods well known in the field. Typically, the desired ingredients are measured by weight or volume, as appropriate, and combined to form a substantially homogeneous mixture using a mixing technique such as milling, blending, shear blending, or homogenization in a suitable vessel. A person with basic experience will be able to determine the most suitable mixing technique and vessel according to the batch size and the physical form of the starting materials and the final composition. Preferably, the APIs, vehicles, and excipients are combined in a homogenizer. The selection of additional excipients, if desired or required, is within the knowledge of the person skilled and will depend on considerations such as the type and physical form of the required composition. The composition is formulated as a composition adapted or suitable for topical administration. Preferably, the pharmaceutical composition is an aqueous formulation. It is understood that any vehicle and excipient used must be acceptable in the sense of being compatible with the other ingredients of the composition and not harmful to the recipient. In some embodiments, the aqueous vehicle is purified water. It is also understood that a composition for topical application is preferably of a physiologically acceptable pH. Preferably, the composition has a final pH of 3.5–4.5. The pharmaceutical compositions of the present invention or the compositions used in the methods of the present invention can be formulated and administered using methods well known in the field. The formulation and administration techniques can be found, for example, in Remington: The Science and Practice of Pharmacy, Loyd V. Allen, Jr. (Ed.), The Pharmaceutical Press, London, 22nd Edition, September 2012. It is understood that it may be useful to incorporate one or more pharmaceutically acceptable excipients into the composition. Excipients for aqueous compositions include, but are not limited to, buffers, stabilizers, chelating agents, tonicity agents, humectants, antioxidants, thickening agents, solubilizing agents, viscosity modifiers, rheology modifiers, and preservatives. Suitable excipients are well known in the field and readily available from commercial sources. Preferably, the excipients are of pharmaceutical grade, e.g., USP or BP grade. Pharmaceutical excipients are described, for example, in Handbook of Pharmaceutical Excipients, Paul J. Sheskey et al., The Pharmaceutical Press, London, eighth edition, August 2017.It will be appreciated that determining whether a particular class of excipient is required and selecting an appropriate excipient will be well within the experience and knowledge of a person with basic expertise. It will also be recognized that an excipient must be chemically inert with respect to the other components of the composition. The concentration of any particular excipient will vary according to its nature, and a person skilled in the art will be able to readily select suitable excipients and determine the required quantity without undue burden or inventive input. For example, excipients may include one or more pH adjusters or buffering agents to adjust the pH of the composition to a physiologically acceptable pH or to maintain the pH of the composition at a physiologically acceptable pH. Acceptable buffering agents are well known in the field. Suitable pH adjusters include acids, such as hydrochloric acid; or bases or alkalis, such as sodium or potassium hydroxide. In some formulations, it may be beneficial to solubilize certain components when preparing a composition as described here. For example, it may be useful to solubilize a corticosteroid or insecticide in a non-aqueous solvent before or concurrently with its introduction into an aqueous base during the preparation of a pharmaceutical composition as described here. Suitable solvents, co-solvents, or solubilizing agents for organic APIs, such as corticosteroids and insecticides, are well known. A person skilled in the art would be able to readily determine whether the use of a solvent / solubilizing agent is desirable or necessary. The selection of particular solubilizing agents or solvents, or classes of solubilizing agents or solvents, and the determination of the quantity of a solubilizing agent or solvent will be well within the experience and knowledge of a person with basic expertise.In some formulations, solubilizing agents include oleoyl macrogel-6 glycerides. In some formulations, solubilizing agents include N-methylpyrrolidone (NMP), propylene glycol, or 2-(2-ethoxyethoxy)ethanol. It will be appreciated that the quantity and selection of solubilizing agents required will depend on the solubility characteristics of the APIs and their concentration in the aqueous composition. A person with basic knowledge can easily determine this based on the... ML / t / ZUZZ / U4U40U general knowledge and the examples described herein without inventive contribution. The solubilizing agents may be present in a composition of the invention in an amount of, for example, from approximately 100 g / L to approximately 200 g / L; or approximately 150 g / L or approximately 130 g / L. Surfactants, such as non-ionic water-dispersible surfactants, are well known in the field of pharmaceutical formulation. They can solubilize and increase the bioavailability of poorly water-soluble active pharmaceutical ingredients (APIs). They can also act as co-emulsifiers in topical formulations to improve emulsion stability. An example of a non-ionic water-dispersible surfactant is oleoyl macrogel-6 glycerides, available as Ladrafil® M 1944. This surfactant may be present in a composition of the invention in an amount of approximately 10 g / L to approximately 30 g / L, for example, approximately 20 g / L. Those skilled in the art will also appreciate that thickening agents, rheology modifiers, or viscosity modifiers can be incorporated into the composition to adjust the viscosity or rheological properties to the requirements for topical application. Suitable thickening agents are well known in the art and include cellulose derivatives, such as hydroxypropyl methylcellulose and carboxymethylcellulose; natural gums, such as sodium alginate, xanthan gum, agar, or carrageenan; pectins; and gelatin. If present, the amount of thickening agent in a composition of the invention will depend on the desired consistency. Thickening, stabilizing, and emulsifying agents or excipients for products formulated as leave-in lotions or conditioners are well known in the art. These excipients are useful because they can provide an advantageous base for the compositions of the invention, which can condition the animal's coat or condition or soothe the animal's skin. In preferred embodiments, a composition of the invention comprises one or more excipients selected from thickening, stabilizing, and emulsifying agents. Excipients suitable for formulating cosmetic, hair care, personal care, and pharmaceutical compositions are well known. One such excipient is a commercially available thickener / stabilizer / emulsifier combination comprising polyquaternium-37, propylene glycol dicaprylate, and PPG-1 Trideceth-6, commercially available from BASF as Salcare® SC96.In some preferred embodiments, the compositions comprise one or more conditioning excipients. In some embodiments, the thickener / stabilizer / emulsifier is present in an amount of approximately 10 g / L to approximately 60 g / L, for example, approximately 20 g / L to approximately 40 g / L, or approximately 30 g / L. In some formulations, the composition comprises a corticosteroid in an amount of approximately 0.025 g / L to approximately 1 g / L; an insecticide selected from a ML / t / zuzz / u^u^oy pyrethrin or a pyrethroid in an amount of approximately 0.5 g / L to approximately 60 g / L; and thickening, stabilizing and emulsifying agents in a total of approximately 10 g / L to approximately 60 g / L; a pharmaceutically acceptable vehicle; and optionally one or more silicones with a total of approximately 25 g / L to approximately 150 g / L. In a preferred embodiment, the composition comprises one or more silicones and one or more thickening agents. In some embodiments, the ratio of silicones to thickening agents is approximately 4:1 to 3:2 or 3:1 to 2:1; for example, approximately 75:30. The combined amount of thickening agent and silicones in the composition typically constitutes approximately 10–12% of the formulation by weight. In some embodiments, the combined amount of silicones and thickening agents present in the formulation is 100 g / L to 200 g / L. A person skilled in the art will recognize that a composition of the invention may be susceptible to microbiological contamination or physical or chemical degradation; therefore, a preservative may be incorporated into the composition to reduce or prevent its degradation or alteration. Suitable preservatives and antioxidants are well known in the art, and the selection of particular preservatives or antioxidants and the determination of the required amount will be well within the experience and knowledge of a person with basic expertise. In some embodiments, an antioxidant is butylhydroxytoluene, for example, in an amount of approximately 0.2 g / L to approximately 1 g / L, such as 0.5 g / L. Preservatives are well known in the art and include one or more of propylene glycol, diazolidinyl urea, and parabens such as methylparaben and propylparaben.The typical amounts of preservatives in a composition as described here range from approximately 5 g / L to approximately 15 g / L, for example, approximately 10 g / L. Preservatives for pharmaceutical and personal care formulations are commercially available. One example is a mixture of propylene glycol, diazolidinyl urea, methylparaben, and propylparaben, commercially available as Germaben II®. A composition of the invention may also include one or more stabilizers. Examples of stabilizers include chelating agents such as the disodium salt dihydrate of ethylenedinitrilotetraacetic acid. The amount of stabilizer used will depend on the circumstances; for example, amounts of approximately 0.5 g / L to approximately 2 g / L, or approximately 1 g / L, are considered. In one particular embodiment, the present invention provides a leave-in conditioner formulation comprising, consisting of, or essentially consisting of: budesonide: approximately 0.25 g / L; permethrin: approximately 40 g / L; μλ / t / zuzz / umMoy silicones, for example, one or more of cyclopentasiloxane, cyclotetrasiloxane and polydimethylsiloxane with terminal hydroxyl in a total amount of approximately 75 g / L; thickening agents, for example, a mixture of Polyquaternium-37 / propylene glycol dicaprate / PPG-1 Trideceth-6, in an amount of approximately 30 g / L; oleoyl macrogel-6 glycerides: approximately 20 g / L; N-methylpyrrolidone: approximately 50 g / L; Propylene glycol: approximately 30 g / L 2-(2-ethoxyethoxy)ethanol: approximately 50 g / L; one or more pharmaceutically acceptable excipients selected from chelating agents, stabilizers, antioxidants, preservatives, and pH adjusters; and Purified water (up to 1000 mL). In some preferred embodiments, the silicones comprise cyclosiloxanes, for example, one or more of cyclopentasiloxane and cyclotetrasiloxane, in an amount of approximately 73 g / L and polydimethylsiloxane with a terminal hydroxyl in a total amount of approximately 2 g / L or 1.95 g / L. If desired, the compositions of the invention may further comprise one or more physiologically active agents. Preferably, any additional physiologically active agent may be formulated as a topical formulation. The additional therapeutically active ingredients may include antibiotics. Other therapeutically active ingredients include analgesics, anti-inflammatory agents, or antipyretics. Methods of invention The compositions described above are used in methods for treating allergic dermatitis caused by insect bites. Therefore, a method is also provided for treating insect bite allergic dermatitis or a symptom thereof in a mammal comprising administering to the mammal an effective amount of a pharmaceutical composition as described herein. Preferably, the mammal is selected from cattle, pigs, sheep, dogs, and horses. In some variations, the mammal is a dog. In some variations, the mammal is an equine, such as a horse or pony. In some variations, the mammal is a goat. In another respect, a pharmaceutical composition as described herein is provided for use in the treatment of insect bite allergic dermatitis or a symptom thereof. A pharmaceutical composition as described herein is also provided for use in therapy. The pharmaceutical composition as described herein may also be used in the manufacture of a medicament for the treatment of insect bite allergic dermatitis or a symptom thereof. MA / t / zuzz / u+u^oy Although other methods of administration are possible, the compositions of the invention are primarily intended for topical application to the skin, coat, or fur of the animal. In the methods or uses described herein, the composition of the invention is released topically. A composition of the invention shall be deemed to be more effective when applied in such a way as to be in contact with the skin, particularly in areas commonly affected by insect bite allergic dermatitis. Queensland itchy lesions are consistent with the preferred feeding sites of insects. For an equine, the composition is normally applied as needed to the coat or skin in one or more areas by pouring on the dorsal line, mane, tail, ears, head, dorsal midline, or ventral midline of the equine. In some examples, the composition is appropriately applied to one or more dorsal areas, such as the forehead, nape, ears, neck, crest, withers, shoulders, or croup, as needed. For a canine, the composition is normally applied to one or more areas of the croup, dorsal thorax, flanks, trunk, or perineal area of ​​the dog. In some examples, the composition of the invention is spread by hand onto the animal's fur, using a suitable circular motion. It will be appreciated that a composition such as the one described here is likely to be more effective when applied to the animal's clean coat. In the case of a leave-in conditioner formulation, whether applied by pouring, spraying, or lotion, the animal's coat should preferably be freshly washed and damp. It will be noted that there will be a variation in how a given dose of the product is applied to an animal. A formulation such as the one described here, when applied to the coat, can be considerably dispersed throughout the hair before reaching the skin. This varies according to the animal species, e.g., dog, horse. It will also depend on factors such as hair length; coat density; hair texture (coarse / fine); the amount of sebum / scales present on the skin surface; and the oiliness of the coat. Furthermore, coat density varies in different parts of the body, with the coat tending to be finer on the shoulders and denser in the croup, tail, and mane areas. Thus, depending on the circumstances, the product may need to be diluted according to the application method.It will be noted that it may be necessary to adjust the quantity and type of excipients and the amount of vehicle present in the formulation to allow for optimal release to the animal's skin. For example, a spray application may be diluted with water. A composition of the invention may be used in any amount that is effective in inhibiting or treating insect bite allergic dermatitis. As used herein, the term "effective amount" refers to an amount of the composition which, when administered according to a desired dosing regimen, provides the desired therapeutic activity for the condition. Dosing may typically occur at intervals of hours, days, weeks, or months. Once-a-weekly application of a composition of the invention is considered adequate. A therapeutically effective amount, or an effective treatment amount, is an amount of the composition which, when administered according to a desired dosing regimen, is sufficient to at least partially achieve the desired therapeutic effect, or delay the onset of, or inhibit the progression of, or partially or totally halt the onset or progression of the condition.An effective preventive amount of the composition, which, when administered according to a desired dosage regimen, is sufficient to at least partially prevent the onset of the condition. The dosage and frequency of administration of the formula will depend on the specific requirements of the mammal being treated. Appropriate dosage amounts and dosage regimens can be determined by the veterinarian and may depend on the severity of the condition, as well as the age, overall health, and weight of the mammal being treated. In some examples, a leave-in lotion or conditioner according to the invention can be applied in approximately 1 to approximately 1.5 g (approximately 1.5 mL, e.g., 1.6 mL) to cover about 0.025 to 0.03 m² of the mammal's skin. In some examples, a pump is adapted to dispense approximately 1.6 mL of a leave-in lotion or conditioner. This can typically cover approximately 0.025 m² (approximately a palm's width) when applied by hand to the animal's coat. In some examples of the invention, the lotion or conditioner may contain approximately 0.0004 g of a corticosteroid, 0.064 g of an insecticide, or approximately 0.0004 g of a corticosteroid, 0.064 g of an insecticide, and 0.12 g of silicones. In some embodiments of the invention, the composition is applied approximately once a week. Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It should be understood that the invention includes all variations and modifications that fall within its scope and effort. To make the invention easily understood and put into practice, particular preferred embodiments will now be described by means of the following non-limiting examples. EXAMPLES The compositions of the invention can be prepared from commercially available active pharmaceutical ingredients, vehicles, and excipients. The compositions can be prepared using conventional methods for preparing pharmaceutical formulations with conventional mixing equipment, such as a mixer, blender, or homogenizer. ML / t / zuzz / u^u^oy EXAMPLE 1 Preparation of the Pharmaceutical Composition (IVP) The following commercially available ingredients were combined by mixing them in a homogenizer: budesonide [corticosteroid; 0.25g]; permethrin [insecticide; 25:75 cis:trans; 40g]; cyclotetrasiloxane / cyclopentasiloxane mixture (Xiameter® PMX-0344) [silicone excipient / conditioner; 60 g]; 13% solution of polydimethylsiloxane with terminal hydroxyl in cyclopentasiloxane and cyclotetrasiloxane (Xiameter® PMX-1401) [viscous silicone conditioner, 15 g]; Polyquaternium-37 / propylene glycol dicaprylate / PPG-1 Trideceth-6 (Saleare® SC96) [thickening agent; 30 g]; oleoyl macrogel-6 glycerides (Labrafil® M 1944) [solubilizing agent, surfactant; 20g]; Disodium salt of ethylenedinitrilotetraacetic acid, dehydrated [chelating agent; 1 g]; N-methylpyrrolidone [solubilizing agent; 50 grams]; propylene glycol [solubilizing agent; 30 g]; 2-(2-ethoxyethoxy) ethanol [solubilizing agent; 50 grams]; butylhydroxytoluene [antioxidant; 0.5 g]; propylene glycol / diazolidinyl urea / methylparaben / propylparaben (Germaben II) [preservatives, 10 g]; purified water [up to 1000 g]; pH modifiers (hydrochloric acid, sodium hydroxide) to pH 3.5 - 4.5. The formulated composition, designated CP or the formulation of Example 1, is suitable as a leave-in conditioner. It was introduced into a pump-action dispenser adapted to dispense a predetermined volume of composition per actuation. The pump typically dispenses approximately 1.6 mL per actuation. EXAMPLE 2 Efficacy Studies Clinical studies were conducted using the formulation of Example 1 in Queensland horses suffering from itch. Horses with Culicoides allergy were treated topically in a blinded trial conducted according to Good Clinical Practice guidelines, specifically the International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products (VICH) Guideline 9, June 15, 2000. This randomized, placebo-controlled study investigated the efficacy of the leave-in conditioner of Example 1 (CP) containing budesonide and permethrin. The objective of this study was to treat Culicoides hypersensitivity (Queensland itch, sweet itch, Q1) in horses. CP has two active ingredients: budesonide (a steroid that relieves itching and inflammation) and permethrin (an insect repellent). Horses were treated with the commercial product (CP), a placebo (control, excipients only, PL), and three comparator products that had varying levels of active ingredients. Reduced budesonide (LB) had 50% less budesonide than CP but the same amount of permethrin. Budesonide only (BO) and permethrin only (PO) had a single active ingredient in the same amount as CP, to demonstrate the effect of that active ingredient alone. Data were collected and analyzed from 51 naturally itch horses (10 horses per group except for 11 receiving only budesonide) from Queensland. Each horse received 40 pumps (approximately 60 grams) applied to the skin once a week for 6 weeks. Each dose was administered by a veterinarian to the areas where itch typically occurs, namely the face, head, neck, flanks, and back. The veterinarian assessed the horses on days 0, 21, and 42, and the owners measured itch and quality-of-life scores. Statistical analysis was performed using GraphPad Prism 8 software. A one-way non-parametric ANOVA (Kruskal-Wallis test with Dunn's multiple comparisons) was used. Lesion scoring. Lesion scores were calculated from four different components: excoriations, scaling and crusting, alopecia, and papules. These are the most common types of lesions in horses with Q1. Scores were calculated at eight different sites on the horses' bodies. At each of the eight sites, the severity of each sign was rated from 0 (none) to 5 (severe). The total lesion score was then calculated by (severity) x (number of signs) x (sites), resulting in a maximum possible total score of 160. Each horse was assigned a score on days 0, 21, and 42. Figure 1 shows the lesion scores in all treatment groups on days 0, 21, and 42, which was the study endpoint. Total lesion scores (maximum score of 160) were similar between groups at baseline (p = 0.6259). On day 21, only CP (p = 0.0012) and on day 42, both CP and PO were significantly different from placebo (p = 0.0003 and p = 0.0366, respectively). Multiple comparisons showed no other differences between treatment groups. Itch score. The owner measured the itch score daily on a scale of 0 to 10 for 42 days using the visual analog scale for pruritus, which assigns an itch score from 1 to 10 based on several indicators of itch in the horse. On day 0, there was no difference between the treatment groups (p = 0.3360). On day 42, only the pruritus score was statistically significantly different from the placebo (p = 0.0483). The results are shown in Figure 2. MA / t / zuzz / u^u^oy Overall treatment response: The overall treatment efficacy score was on a 4-level scale from 1 (poor) to 4 (excellent) and was used as a measure of overall improvement, assessed by the veterinarian on days 21 and 42. A total of 70% of the horses in the CP group showed an excellent treatment response on days 21 and 42. On days 21 and 42, only the CP group showed a statistically significant difference (p = 0.0019) compared to the placebo control. (FIGURE 3). Summary: The following table (Table 1) shows the results for all major outcome measures, namely lesion score, itch score, quality of life, and overall treatment response (treatment efficacy). Table 1 Treatment Group Lesion Score Itch Score Quality of Life Score Treatment Efficacy Day 0 Day 42 Day 0 Day 42 Day 0 Day 42 Day 0 Day 42 CP (Example 1) 74 11 6.9 2.7 4.5 8.4 3.7 3.5 LB (Reduced Budesonide) 70 22 7.3 3.7 4.6 7.2 3.0 3.1 BO (Budesonide Only) 77 29 7.3 2.9 4.1 8.5 2.6 3.1 PO (Permethrin Only) 68 18 7.5 3.4 4 7.7 3.2 3.2 Placebo / Control (Excipients Only) 74 54 7.6 6.3 4.7 6.1 2.1 1.8 These data show that CP is the only treatment that demonstrates a statistically significant difference in the study outcome measures compared to placebo. These data show a clear reduction in lesion scores, itching scores, and overall treatment response, as well as an improvement in quality of life with the formulation in example 1 (CP). Sleep data were collected using activity monitors on horses to track their movements. Sleep data were calculated from the time (in minutes) the horses remained still without any movement. Horses in the CP treatment group were generally observed to spend more time resting than horses in the other treatment groups. Horses in the placebo / control group spent the least amount of time resting. These data support the hypothesis that horses treated with the CP composition are less restless and sleep or rest more. Following the initial study, 42 horse owners opted to continue with phase 2 of the trial, where they used the product for one year as needed. The results showed that most owners used significantly less than the full dose and only used it occasionally. No significant side effects were observed under these conditions. A safety study was conducted on healthy horses using the recommended doses of 1x, 3x, and 5x for 6 weeks and 1x for 12 weeks. No abnormalities were detected in blood or skin (biopsies) at the full 6-week dose or even at 5 times the full dose. Therefore, the product was considered safe to use. These data demonstrate that the formulations of the invention can be used to treat the symptoms of IBH, or Queensland itch. It is observed that the symptoms of at least one of the conditions, including excoriations, scaling and crusting, alopecia, and papules, are rapidly reduced, and the overall efficacy of the treatment is considered beneficial. In general, a significant reduction in the horse's itching and distress was observed. The well-being of the affected animal was observed to improve with no side effects or with very mild side effects. This is considered useful as a safe and effective treatment that works within a reasonable timeframe. It requires only one application per week and lacks the common complications of systemic corticosteroids. Therefore, the formulations of the invention are considered to be useful in the treatment of animals suffering from the particularly cruel, painful, and distressing condition of IBH. The description of each patent, patent application, and publication cited herein is incorporated herein by reference in its entirety. The citation of any reference herein should not be construed as an admission that such reference is available as background to the invention for the present application. Throughout this disclosure, the objective has been to describe preferred embodiments of the invention without limiting the invention to any specific embodiment or set of features. Therefore, those skilled in the art will appreciate that, in light of this disclosure, various modifications and changes can be made to the particular embodiments exemplified without departing from the scope of the present invention. All such modifications and changes are intended to be included within the scope of the appended claims.

Claims

NOVELTY OF THE INVENTION Having described the present invention as above, the following is considered novel and is therefore claimed as property: CLAIMS 1. A pharmaceutical composition for topical application characterized in that it comprises a corticosteroid; an insecticide selected from pyrethrin insecticides and pyrethroid insecticides; and a pharmaceutically acceptable vehicle.

2. The composition according to claim 1, characterized in that it further comprises a silicone excipient.

3. The composition according to claim 2, characterized in that the silicone excipient is selected from one or more of cyclopentasiloxane, cyclotetrasiloxane and dimethiconol.

4. The composition according to any one of claims 1 to 3, characterized in that the corticosteroid is clobetasol propionate; betamethasone dipropionate; budesonide; halobetasol propionate; diflorasone diacetate; fluocinonide; halcinonide; amcinonide; desoximetasone; triamcinolone acetonide; mometasone furoate; fluticasone propionate; halometasone; fluocinolone acetonide; hydrocortisone valerate; hydrocortisone butyrate; flurandrenolide; desonide; alclometasone dipropionate; fluocinolone acetonide; hydrocortisone; betamethasone valerate; diflucortolone valerate; hydrocortisone butyrate; methylprednisolone aceponate; clobetasone butyrate; or triamcinolone acetonide.

5. The composition according to any of claims 1 to 4, characterized in that the corticosteroid is budesonide.

6. The composition according to any of claims 1 to 5, characterized in that the insecticide is allethrin, bifenthrin, permethrin, phenothrin, resmethrin, tefluthrin, tetramethrin, cyfluthrin, cyhalothrin, cypermethrin, deltamethrin, fenvalerate, fenpropathrin, flucythrinate, flumethrin, fluvalinate, or tralomethrin.

7. The composition according to any of claims 1 to 6, characterized in that the insecticide is permethrin.

8. The composition according to any of claims 1 to 7, characterized in that the corticosteroid is in an amount of approximately 0.05 g / L to approximately 1 g / L, preferably approximately 0.25 g / L.

9. The composition according to any of claims 1 to 8, characterized in that the insecticide is in an amount of approximately 10 g / L to approximately 60 g / L, preferably approximately 40 g / L.

10. The composition according to any of claims 1 to 9, MA / IZ / ¿U¿¿ / U4U40» 35 characterized in that the ratio of corticosteroid to insecticide is about 1:

160.

11. The composition according to any of claims 1 to 10, characterized in that the silicone is in an amount of approximately 25 g / L to approximately 150 g / L, preferably approximately 75 g / L.

12. The composition according to any of claims 1 to 11, characterized in that the ratio of corticosteroid to insecticide is about 1:

160.

13. A composition according to claim 1 formulated for topical administration characterized in that it comprises: budesonide in an amount of approximately 0.05 g / L to approximately 1 g / L; permethrin in an amount of approximately 10 g / L to approximately 80 g / L; one or more silicones in an amount of approximately 25 g / L to approximately 150 g / L; and a pharmaceutically acceptable aqueous vehicle; and optionally one or more excipients selected from thickening agents, solubilizing agents, chelating agents, antioxidants, preservatives, and pH modifiers.

14. A composition according to claim 1 formulated for topical administration characterized in that it comprises: budesonide in an amount of approximately 0.25 g / L; permethrin in an amount of approximately 40 g / L; one or more silicones in an amount of approximately 75 g / L; thickening agents in an amount of approximately 30 g / L; one or more excipients selected from solubilizing agents, chelating agents, antioxidants, preservatives, and pH modifiers; and purified water to 1 L.

15. A composition according to claim 14, characterized in that the silicones are one or more of cyclopentasiloxane, cyclotetrasiloxane and dimethiconol.

16. A composition according to claim 14 or claim 15, characterized in that the thickening agent is a mixture of Polyquaternium-37, propylene glycol dicaprylate and PPG-1 Trideceth-6.

17. The composition according to any of claims 1 to 16, characterized in that the composition is formulated as a conditioner, a leave-in conditioner, a lotion, a spray, a cream, an ointment or a pour-on formulation.

18. The composition according to any of claims 1 to 17, characterized in that the composition is formulated as a leave-in conditioner.

19. The composition according to any of claims 1 to 16, characterized in that the composition is adapted for application by pouring or spraying.

20. A method for treating allergic insect bite dermatitis in a mammal characterized in that it comprises the topical application of a pharmaceutical composition according to any of claims 1 to 19 to a mammal in need thereof.

21. The method according to claim 20, characterized in that the mammal is selected from cattle, pigs, sheep, dogs or equines; preferably the mammal is a dog or an equine, such as a horse.

22. The method according to claim 20, characterized in that the composition is applied to the fur or skin of the dorsal line, mane area, tail area, mid-dorsal line, ears, head or ventral area of ​​an equine.

23. The method according to claim 20, characterized in that the composition is applied to the rump, dorsal thorax, sides, trunk, ears, head or perineal area of ​​a dog.

24. A topical composition according to any of claims 1 to 19 for use in the treatment of allergic insect bite dermatitis.

25. Use of a topical composition according to any of claims 1 to 19 in the preparation of a medicament for the treatment of allergic insect bite dermatitis.